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Abstract
Background: Liposarcomas are the most common class of soft tissue sarcomas, and myxoid liposarcoma is the second most
common liposarcoma. EWSR1-DDIT3 is a chimeric fusion protein generated by the myxoid liposarcoma-specific
chromosomal translocation t(12;22)(q13;q12). Current studies indicate that multipotent mesenchymal cells are the origin
of sarcomas. The mechanism whereby EWSR1-DDIT3 contributes to the phenotypic selection of target cells during
oncogenic transformation remains to be elucidated.
Methodology/Principal Findings: Reporter assays showed that the EWSR1-DDIT3 myxoid liposarcoma fusion protein, but
not its wild-type counterparts EWSR1 and DDIT3, selectively repressed the transcriptional activity of cell lineage-specific
marker genes in multipotent mesenchymal C3H10T1/2 cells. Specifically, the osteoblastic marker Opn promoter and
chondrocytic marker Col11a2 promoter were repressed, while the adipocytic marker Ppar-c2 promoter was not affected.
Mutation analyses, transient ChIP assays, and treatment of cells with trichostatin A (a potent inhibitor of histone
deacetylases) or 5-Aza-29-deoxycytidine (a methylation-resistant cytosine homolog) revealed the possible molecular
mechanisms underlying the above-mentioned selective transcriptional repression. The first is a genetic action of the EWSR1-
DDIT3 fusion protein, which results in binding to the functional C/EBP site within Opn and Col11a2 promoters through
interaction of its DNA-binding domain and subsequent interference with endogenous C/EBPb function. Another possible
mechanism is an epigenetic action of EWSR1-DDIT3, which enhances histone deacetylation, DNA methylation, and histone
H3K9 trimethylation at the transcriptional repression site. We hypothesize that EWSR1-DDIT3-mediated transcriptional
regulation may modulate the target cell lineage through target gene-specific genetic and epigenetic conversions.
Conclusions/Significance: This study elucidates the molecular mechanisms underlying EWSR1-DDIT3 fusion protein-
mediated phenotypic selection of putative target multipotent mesenchymal cells during myxoid liposarcoma development.
A better understanding of this process is fundamental to the elucidation of possible direct lineage reprogramming in
oncogenic sarcoma transformation mediated by fusion proteins.
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Introduction
Sarcoma is the collective name for non-epithelial, non-
hematopoietic malignant tumors that arise from the embryonic
mesoderm. Several sarcomas have specific chromosomal translo-
cations and resultant fusion genes [1]. In certain subsets of
sarcomas that are believed to originate from multipotent
mesenchymal cells, a specific sarcoma phenotype may manifest
through transcriptional regulation by specific fusion proteins,
modulating target cell lineages [2–5].
Liposarcomas are the most common class of soft tissue sarcomas
and are divided into separate clinicopathological entities with
distinctive morphological spectra and associated genetic changes
[6]. Myxoid liposarcoma (MLS) denotes one such entity and is the
second most common liposarcoma after well-differentiated
liposarcoma [7]. A significant proportion of MLS has a
cytogenetic hallmark of chromosomal translocation,
t(12;16)(q13;p11). This translocation leads to fusion of translocated
in liposarcoma (TLS; also known as fused in sarcoma, FUS) and
DNA damage-inducible transcript 3 (DDIT3; also known as
CCAAT/enhancer-binding protein (C/EBP) homologous protein,
CHOP; originally named as growth arrest- and DNA damage-
inducible gene 153, GADD153) genes, resulting in the production
of the TLS-DDIT3 fusion protein [8–13].
In other subset of MLS, a variant chromosomal translocation,
t(12;22)(q13;q12), results in fusion of Ewing’s sarcoma (EWSR1)
and DDIT3 genes [10,11,14–16]. However, the function of the
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36682resultant fusion protein EWSR1-DDIT3 during oncogenic
transformation is not clear. If MLS originates from multipotent
mesenchymal cells, EWSR1-DDIT3 may act as an aberrant
transcription factor and affect the phenotypic selection of
uncommitted target cells [17,18]. To test this hypothesis, we
analyzed whether EWSR1-DDIT3 affected the transcriptional
potential of lineage-specific marker genes in mouse multipotent
mesenchymal C3H10T1/2 cells. The osteopontin (Opn), alpha 2
chain of type XI collagen (Col11a2), and peroxisome proliferator-
activated receptor-gamma (Ppar-c) genes were selected to
represent expression of osteoblastic, chondrocytic, and adipocytic
phenotypes, respectively. We found that EWSR1-DDIT3 re-
pressed the promoter activity of Opn and Col11a2 but not that of
Ppar-c2, and we further explored the potential molecular
mechanisms underlying this selective transcriptional repression.
Results
Innate mouse multipotent mesenchymal C3H10T1/2 cells
expressed Opn, Col11a2, and Ppar-c mRNA transcripts
Opn is a phosphorylated glycoprotein originally isolated from
bone [19] and is a marker for the osteoblastic cell phenotype [20].
Type XI collagen is almost exclusively found in the cartilage.
Col11a2 gene encodes its alpha 2 chain [21], and Col1la2
expression is a marker for the chondrocytic cell phenotype [22–
24]. Ppar-c is a well-known master regulator of adipogenesis [25].
Two isoforms of Ppar-c, Ppar-c1 and Ppar-c2, are generated by
alternative splicing. Ppar-c2 is more closely related to the
adipocytic cell phenotype [26]. Reverse transcription-polymerase
chain reaction (RT-PCR) analysis demonstrated that mRNA
transcripts for Opn, Col11a2, and Ppar-c genes were detectable in
innate C3H10T1/2 cells (Figure 1). Thus, C3H10T1/2 cells
simultaneously expressed multiple cell lineage-specific marker
genes for osteoblastic, chondrocytic, and adipocytic phenotypes
according to their multipotency [27–29].
EWSR1-DDIT3 fusion protein, but not its wild-type
counterparts EWSR1 and DDIT3, repressed the promoter
activity of Opn and Col11a2 but not that of Ppar-c2
A report of successful transformation in the same cellular
background, i.e., by induction of a single oncogenic event
(specifically, induction of the EWSR1 fusion protein, EWSR1-
FLI1) [30], encouraged us to analyze the molecular mechanism of
sarcomagenesis caused by EWSR1-DDIT3 using C3H10T1/2
cells. To investigate whether the EWSR1-DDIT3 fusion protein
influences transcription of Opn, Col11a2, or Ppar-c2 genes, we
first monitored the promoter activity of the 2857/+91 fragment of
the mouse Opn promoter-, 2742/+380 fragment of the mouse
Col11a2 promoter-, and 2615/+64 fragment of the mouse Ppar-
c2 promoter-luciferase reporter constructs (pGL3-Opn, pGL3-
Col11a2, and pGL3-Ppar-c2, respectively) in C3H10T1/2 cells.
Transient cotransfection experiments demonstrated that each
promoter construct exhibited promoter activity when transfected
with the empty vector, pFLAG-CMV4 control. Overexpressing
EWSR1-DDIT3 under the control of a CMV promoter using the
pFLAG-CMV4 EWSR1-DDIT3 expression vector significantly
repressed Opn and Col11a2 promoter activities by 79% and 78%,
respectively; however, overexpressing EWSR1 and DDIT3 did not
(Figure 2A–C). On the other hand, Ppar-c2 promoter activity was
not significantly affected by EWSR1-DDIT3 or EWSR1 overex-
pression, but it was very mildly repressed by wild-type DDIT3
(Figure 2D). The latter finding is consistent with the inhibitory
action of DDIT3 on the Ppar-c2 promoter in rat osteosarcoma-
derived UMR106 cells [31]. These data indicate that the EWSR1-
DDIT3 fusion protein selectively represses transcription from
osteoblastic and chondroblastic lineage marker genes, but not from
an adipocytic lineage marker gene, in multipotent mesenchymal
C3H10T1/2 cells. Further experiments using human mesenchy-
mal stem cells (hMSCs, Lonza Corporation, Walkersville, MD,
USA) [32,33] also showed that the EWSR1-DDIT3 fusion protein
selectively repressed transcription from Opn and Col11a2
promoters, but not from Ppar-c2 promoter (Figure 2E–G). These
observations suggested that the selective gene repression by the
EWSR1-DDIT3 fusion protein may be more than an artifact
dependent on the uniqueness of C3H10T1/2 cell line.
Figure 1. Innate mouse multipotent mesenchymal C3H10T1/2
cells expressed multiple lineage-specific marker genes. RT-PCR
analysis detected osteoblastic marker Opn (lane 1), chondrocytic marker
Col11a2 (lane 3), and adipocytic marker Ppar-c (lane 5) mRNA
transcripts in C3H10T1/2 cells. Mouse osteosarcoma cell line LM8 (lane
2), mouse embryonic skeleton cells (lane 4), and mouse preadipocytic
cell line 3T3-L1 (lane 6) were analyzed as positive controls for Opn,
Col11a2, and Ppar-c gene expression, respectively. The b-actin
transcript level served as a loading control for each reaction.
doi:10.1371/journal.pone.0036682.g001
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36682Figure 2. EWSR1-DDIT3 fusion protein selectively repressed promoter activities of lineage-specific marker genes in C3H10T1/2
cells as well as in hMSCs. (A) Schematic of domain structure of EWSR1, DDIT3, and EWSR1-DDIT3. SYQG-rich, Ser-Tyr-Gln-Gly-rich transactivating
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activity of Opn and Col11a2 genes required its intact
leucine zipper domain
Molecular composition of EWSR1-DDIT3 revealed that the C-
terminal DDIT3 sequence contained a leucine zipper (LZ) dimer
forming domain (Figure 3A). DDIT3 is a dimer forming
transcription factor and it can not bind DNA as a monomer nor
form dimers with itself. To test the possibility that EWSR1-DDIT3
affects Opn and Col11a2 promoters by binding to potential target
sites within them, two forms of mutant EWSR1-DDIT3
expression vectors were generated. One mutant, EWSR1-DDIT3
del LZ lacked 38 amino acids at the C-terminal end, which
contained the entire LZ domain. In another mutant, EWSR1-
DDIT3 mut LZ, all five leucine residues within the dimer forming
domain were mutated to glycine residues. Consequent cotransfec-
tion experiments in C3H10T1/2 cells documented that Opn and
Col11a2 promoter activities were significantly increased by
overexpression of EWSR1-DDIT3 del LZ or EWSR1-DDIT3
mut LZ than of EWSR1-DDIT3 (Figure 3B and 3C). These
observations revealed that the repressive action of EWSR1-
DDIT3 required its intact LZ domain for binding to potential
target sites within each promoter.
Function of potential C/EBP-binding sites within Opn and
Col11a2 promoters in mouse multipotent mesenchymal
C3H10T1/2 cells
The LZ dimer forming domain and DNA-binding domain of
DDIT3 are highly conserved among members of the C/EBP
protein family of transcription factors. To identify the DNA
sequence within Opn and Col11a2 promoters that the EWSR1-
DDIT3 fusion protein might target in multipotent mesenchymal
C3H10T1/2 cells, we inspected each promoter sequence and
relevant literature. The Opn promoter contained an inverted
CCAAT box located at 253 to 249 from the transcription start
site, which mediated transcriptional stimulation by v-Src in
NIH3T3 cells (Figure 4A) [34]. Inspection of the Col11a2
promoter sequence revealed a novel candidate C/EBP-binding
site consisting of two half sites for CREB or AP-1, 59-TCA-39,
located at 2220 to 2218 and 2211 to 2209, and C/EBP half-
site, 59-GCAAT-39, located at 2232 to 2228 from the
transcription start site (Figure 4B) [22]. Activation of the mouse
alpha 1 chain of the type X collagen (Col10a1) gene by C/EBP b
via these two half sites for CREB or AP-1 and the C/EBP half-site
was shown in ATDC5 cells [35]. Mutating the inverted CCAAT
box in the Opn promoter construct to aaAAT (Opn mut) and the
C/EBP half-site in the Col11a2 promoter construct to GCccT
(Col11a2 mut) significantly reduced the luciferase activity by 84%
and 70%, respectively, when transiently transfected into
C3H10T1/2 cells (Figure 4A and 4B). In contrast, Ppar-c2
promoter activity was not significantly influenced by deleting
tandem repeats of C/EBP-binding sites located between 2615 to
2320, which were shown to mediate glucocorticoid-induced
adipocytic differentiation of C3H10T1/2 cells (Figure 4C) [36].
These findings suggest that Opn and Col11a2 promoter activities
depended on potential C/EBP-binding sites, which could be
targets for EWSR1-DDIT3 in innate mouse multipotent mesen-
chymal C3H10T1/2 cells. Further experiments using hMSCs
showed that mutating the putative C/EBP-binding sites signifi-
cantly decreased transcriptional activities from Opn, Col11a2, and
Ppar-c2 promoters (Figure S1A–C). These observations, unlike
those in C3H10T1/2 cell line, indicated that hMSCs positively
utilized the proximal C/EBP-binding site of the tandem repeat
within the Ppar-c2 promoter.
EWSR1-DDIT3 fusion protein bound potential C/EBP-
binding sites within Opn and Col11a2 promoters in vivo
To explore further the role of EWSR1-DDIT3 in the regulation
of Opn and Clo11a2 promoters in vivo, we performed transient
chromatin immunoprecipitation (ChIP) assays [37] with some
modifications. Use of transient ChIP assays that measure the
interaction of proteins with plasmid-based sequences allowed the
determination of the role of specific local elements in the
interaction of EWSR1-DDIT3 with Opn and Col11a2 promoters
[38,39]. C3H10T1/2 cells were transiently transfected with the
various reporter constructs described above in permutational
combinations with the various FLAG-tagged EWSR1-DDIT3
expression vectors. Promoter sequences associated with FLAG-
tagged proteins were immunoprecipitated from the soluble nuclear
material containing reporter plasmids, which was cross-linked by
formaldehyde and enzymatically sheared to 200–1500 bp
fragments, and then analyzed by semiquantitative PCR using
primers specific for the reporter construct. Immunoprecipitation
performed using normal immunoglobulin (IgG) served as a
negative control. Using plasmid-specific primers, we were able to
distinguish the reporter constructs from the endogenous gene
promoters. As expected from the results of the abovementioned
promoter-luciferase reporter assays, FLAG-tagged EWSR1-
DDIT3 interacted with wild-type Opn and Col11a2 promoters,
while EWSR1-DDIT3 del LZ and EWSR1-DDIT3 mut LZ did
not (Figure 5A and 5B). Importantly, mutation of the potential C/
EBP site within each construct eliminated the binding of wild-type
EWSR1-DDIT3 to the promoter. These results indicated that
EWSR1-DDIT3 bound to the potential C/EBP site within Opn
and Col11a2 constructs thorough the DNA-binding domain and
repressed gene transcription in vivo.
domain; RGG, regions with multiple Arg-Gly-Gly repeats; RNP-CS, ribonucleoprotein consensus sequence; TAD, transcriptional activation domain; BR,
basic amino-acid-rich dimerization domain; LZ, leucine zipper DNA-binding domain. Asterisks (*) designate 27 amino acid residues originating from
DNA sequences upstream of the translation start site of DDIT3 (broken line), which are translated after in-frame fusion to EWSR1. Arrows indicate
points of fusion. (B–D) Effect of EWSR1-DDIT3, EWSR1, and DDIT3 expression vectors on the activities of Opn (B), Col11a2 (C), and Ppar-c2( D)
promoter-luciferase constructs 48 h after transfection in C3H10T1/2 cells. EWSR1-DDIT3, but not its wild-type counterparts EWSR1 or DDIT3,
repressed Opn and Col11a2 promoter activities. However, Ppar-c2 promoter activity was not repressed. Transfection in duplicate was repeated at
least three times, and the results are shown as averages 6 SE. p values calculated by ANOVA were 0.001, 0.0159, and 0.005, for Opn, Col11a2, and
Ppar-c2, respectively. Asterisks (*) indicate statistical significance (p,0.05) following Tukey–Kramer post-hoc test. N.S., not significant. (E–G) Human
bone marrow-derived mesenchymal stem cells (hMSCs) were purchased from Lonza Corporation, Walkersville, MD, USA, and cultured in MSC growth
media (MSCGM-CD
TM BulletKit
TM, Lonza) with penicillin (100 U/ml), streptomycin (100 mg/ml), and amphotericin B (0.25 mg/ml) under 5% CO2 at
37uC. Opn (E), Col11a2 (F), or Ppar-c2( G) promoter activity was analyzed from cell lysates extracted from cells cotransfected with pFLAG-CMV4
control, EWSR1-DDIT3, EWSR1, or DDIT3 48 h after transfection. These constructs were cotransfected with an internal control vector (Renilla). The
luciferase activities were expressed as relative activity to that of the promoter-less reporter vector (pGL3 basic). Transfection in duplicate was
repeated at least three times and the results are shown as average 6 SE. p values calculated by ANOVA were 0.0445, ,0.0001, and 0.2846, for Opn,
Col11a2, and Ppar-c2, respectively.
doi:10.1371/journal.pone.0036682.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36682Figure 3. Intact LZ dimer forming domain was essential for EWSR1-DDIT3-mediated repression of Opn and Col11a2 promoter
activities. (A) Schematic drawing of EWSR1-DDIT3 and two mutants. SYQG-rich, Ser-Tyr-Gln-Gly-rich transactivating domain; TAD, transcriptional
activation domain; BR, basic amino-acid-rich dimerization domain; LZ, leucine zipper dimerforming domain. Asterisks (*) designate 27 amino acid
residues originating from DNA sequences upstream of the translation start site of DDIT3. EWSR1-DDIT3 del LZ lacks the entire LZ composed of 38 C-
terminal amino acid residues (broken line). In EWSR1-DDIT3 mut LZ, all five leucine residues in LZ are converted to glycine residues, as designated. (B
and C) Effect of EWSR1-DDIT3 or two forms of mutant expression vectors on the activities of Opn (B) and Col11a2 (C) promoter-luciferase constructs
48 h after transfection in C3H10T1/2 cells. Opn and Col11a2 promoter activities were significantly increased by EWSR1-DDIT3 del LZ and EWSR1-
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36682DDIT3 mut LZ than by EWSR1-DDIT3. Transfection in duplicate was repeated at least three times, and the results are shown as averages 6 SE. p values
calculated by ANOVA were 0.0001 for Opn and 0.0003 for Col11a2. Asterisks (*) indicate statistical significance (p,0.05) following Tukey–Kramer post-
hoc test.
doi:10.1371/journal.pone.0036682.g003
Figure 4. Identification of potential C/EBP-binding sites within Opn and Col11a2 promoters in C3H10T1/2 cells. (A) An inverted
CCAAT box (boxed) of the pGL3-Opn promoter construct was mutated as designated to produce pGL3-Opn mut. The pGL3-Opn mut exhibited
significantly reduced promoter activity. (B) A half C/EBP site (boxed) of the pGL3-Col11a2 promoter construct was mutated as designated to produce
pGL3-Col11a2 mut. The pGL3-Col11a2 mut exhibited significantly reduced promoter activity. (C) The pGL3-Ppar-c2 promoter construct containing
tandem repeats of C/EBP-binding sites (boxed) and its deletion mutants, pGL3-334 (lacking the distal C/EBP binding site I) and pGL3-320 (lacking
both C/EBP-binding sites I and II), exhibited comparable activity. The luciferase activities were expressed as fold inductions; each activity relative to
that of the promoter-less reporter vector (pGL3 basic). Transfection in duplicate was repeated at least three times, and the results are shown as
averages 6 SE. Asterisks (*) indicate statistical significance (p,0.05) calculated by unpaired t-test.
doi:10.1371/journal.pone.0036682.g004
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endogenous C/EBPb, but not that of C/EBPa, to C/EBP-
binding sites within Opn and Col11a2 promoters
DDIT3 forms heterodimers with a variety of other LZ dimer
forming domain-containing transcription factors. The DDIT3-
derived fusion proteins also form heterodimers. C/EBPa and C/
EBPb were detectable at protein level in C3H10T1/2 cells, and
C/EBPb was more abundantly expressed than C/EBPa at mRNA
level (Figure S2A and S2B). Based on our earlier observations
showing the critical role of C/EBP-binding sites within Opn and
Col11a2 promoters for gene transcription in innate mouse
Figure 5. Interaction of EWSR1-DDIT3 and potential C/EBP-binding sites within Opn and Col11a2 promoters in vivo. Transient ChIP
assays using an antibody against the N-terminal FLAG epitope or normal IgG. C3H10T1/2 cells were transfected with Opn (A) or Col11a2 (B) luciferase
reporter plasmids plus FLAG-tagged expression vectors. Promoter DNA fragments containing potential C/EBP-binding sites (open box) were
immunoprecipitated with EWSR1-DDIT3 when wild-type Opn (pGL3-Opn) and Col11a2 (pGL3-Col11a2) promoter constructs were analyzed. Either
deleting (EWSR1-DDIT3 del LZ, broken line) or mutating (EWSR1-DDIT3 mut LZ, filled box) the LZ dimer forming domain of EWSR1-DDIT3 or mutating
potential C/EBP-binding sites within Opn (inverted CCAAT box, pGL3-Opn mut, filled box) and Col11a2 (half C/EBP site, pGL3-Col11a2 mut, filled box)
promoters eliminated the protein–DNA interaction. As indicated by the arrows, the forward PCR primers are promoter sequence-specific primers and
locate upstream to the potential C/EBP-binding site (open box), while the reverse PCR primer pGL3 is a plasmid-specific primer.
doi:10.1371/journal.pone.0036682.g005
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EWSR1-DDIT3 to C/EBP-binding sites within Opn and Col11a2
promoters, we speculated that EWSR1-DDIT3 might affect the
function of endogenous C/EBP protein family of transcription
factors. To address this possibility, we continued the transient
ChIP assay using antibodies against C/EBPa and C/EBPb in cells
transfected with the empty CMV promoter-FLAG plasmid or
FLAG-tagged EWSR1-DDIT3 expression vector together with
Opn and Col11a2 reporter constructs. Immunoprecipitation
performed using IgG served as a negative control. As shown in
Figure 6A and 6B, in the absence of EWSR1-DDIT3, both C/
EBPa and C/EBPb were able to bind to C/EBP sites containing
segments of Opn and Col11a2 promoters. Interestingly, EWSR1-
DDIT3 overexpression reduced the amount of promoter frag-
ments immunoprecipitated with an antibody against C/EBPb,
while it had a negligible impact when an antibody against C/
EBPa was used (Figure 6A and 6B). Among the abovementioned
two major members of the C/EBP family, previous studies have
provided evidence that C/EBPb may promote osteoblastic
differentiation of C3H10T1/2 cells via the C/EBP site [40] and
that DDIT3 prevents C/EBPb binding to the C/EBP site by
forming heterodimers [41]. The mRNA level for C/EBPa seemed
increased and that for C/EBPb decreased, with no statistical
significance (Figure S2B). Collectively, these data could indicate
that EWSR1-DDIT3 represses Opn and Col11a2 gene transcrip-
tion by interfering, at least in part, with endogenous C/EBPb
function.
Histone deacetylases were involved in EWSR1-DDIT3-
mediated repression of Opn and Col11a2 transcriptional
activities
Histone modifications play a critical role in transcriptional
control, and among such modifications, lysine acetylation is
generally correlated with transcriptional activation [42,43].
Histone acetylation levels are controlled by histone acetylases
and histone deacetylases (HDACs). To further elucidate the
mechanisms by which EWSR1-DDIT3 repressed gene transcrip-
tion, we investigated the influence of pharmacological modulators
of gene expression by treating transfected cells with trichostatin A
(TSA), a potent inhibitor of HDACs [44], 24 h after transfection.
Transfected cells in control plates were not treated with TSA and
were used to calculate fold derepression by TSA. The results
showed that the ability of EWSR1-DDIT3 to repress Opn and
Col11a2 promoter activities was significantly attenuated by TSA-
mediated inhibition of HDACs (Figure 7A and 7B). In addition,
transient ChIP assays using an anti-HDAC1 antibody revealed
enhanced binding of HDAC1 to C/EBP sites containing segments
of Opn and Col11a2 promoters in the presence of EWSR1-
DDIT3, when cells transfected with the empty CMV promoter-
FLAG plasmid or FLAG-tagged EWSR1-DDIT3 expression
vectors plus Opn and Col11a2 reporter constructs were analyzed
(Figure 7C and 7D). These results implied the potential
involvement of HDACs at the gene repression site by EWSR1-
DDIT3 in vivo. In contrast, the repressive action of anacardic acid
(AA, Sigma), a small molecule compound which inhibits histone
acetyltransferase (HAT) activity of p300 and PCAF [45,46], on
promoter activities from both promoters was significantly
attenuated by overexpressing EWSR1-DDIT3 (Figure S3A and
S3B). This observation implies that EWSR1-DDIT3 may interfere
with HAT activity of certain promoters at the site of transcription
in C3H10T1/2 cells.
DNA methylation contributed to transcriptional
repression of Col11a2 by EWSR1-DDIT3
DNA methylation is another category of epigenetic modification
[43] and has been well documented as a mediator of transcrip-
tional repression [47]. DNA methylation and histone deacetylation
function synergistically through the formation of transcriptional
repressor complexes that silence gene expression by establishing a
repressive chromatin environment [48–50]. We analyzed the
influence of pharmacological modulators of DNA methylation by
treating transfected cells with 5-Aza-29-deoxycytidine (AZA), a
methylation-resistant cytosine analog [51], 24 h after transfection.
Transfected cells in the control plate were not treated with AZA
and were used to calculate fold derepression by AZA. Whereas the
ability of EWSR1-DDIT3 to repress the Col11a2 promoter
deteriorated significantly in the presence of AZA, its ability to
repress the Opn promoter was not profoundly influenced by AZA-
mediated inhibition of DNA methylation (Figure 8A and 8B). The
differential effect of AZA on Opn and Col11a2 promoters might
result from differences in their structural class [52], i.e., the Opn
promoter contains a TATA-like sequence (TTTAAA) at 227 to
222 from the transcription start site [53], while the Col11a2
promoter does not have a proper TATA box [22] but rather
contains several SP1-binding sites [54], typical of such TATA-less
class promoters [55]. These data indicated a potential involvement
of DNA methylation in repression of TATA-less and high-CpG
Col11a2 promoter by EWSR1-DDIT3. On the other hand,
adding temozolomide (TMZ, Sigma), a DNA methylating
chemotherapeutic drug [56,57], did not apparently influence the
activity from both promoters in 10T1/2 cells (Figure S4A and
S4B).
EWSR1-DDIT3 influenced levels of acetylation or
trimethylation at lysine 9 of histone 3 around Opn and
Col11a2 promoters
Histone deacetylation, DNA methylation, and methylation at
lysine 9 of histone 3 (H3K9) are the best-characterized covalent
modifications associated with a repressed chromatin state [58,59].
We assessed the levels of acetylation or trimethylation at H3K9
around Opn and Col11a2 promoters by transient ChIP assays in
cells transfected with the empty CMV promoter-FLAG plasmid or
FLAG-tagged EWSR1-DDIT3 expression vectors together with
Opn and Col11a2 reporter constructs. Our data demonstrated
that EWSR1-DDIT3 overexpression decreased the amount of
Opn and Col11a2 promoter fragments immunoprecipitated with
an antibody against acetylated H3K9 (Figure 9A and 9B). When
an antibody against trimethylated H3K9 was used, relative values
of protein–DNA interaction for Col11a2 were increased by
EWSR1-DDIT3, while those for Opn did not change (Figure 9A
and 9B). The ratio of acetylated H3K9 to trimethylated H3K9
around Opn and Col11a2 promoter segments was significantly
decreased by EWSR1-DDIT3 (Figure 9C), which reflected
epigenetic silencing of gene transcription [60–62].
Discussion
It is becoming increasingly evident that many transforming
genetic alterations responsible for sarcoma development are found
in multipotent mesenchymal cells [2–5]. The induction of several
types of sarcomas, such as EWSR1, MLS, and alveolar
rhabdomyosarcoma, by overexpression of specific oncogenic
fusion proteins in multipotent mesenchymal cells has been
documented [63–66]. However, the exact molecular mechanisms
by which these fusion proteins exert oncogenic transformation
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remain uncertain.
In this study, we showed that the EWSR1-DDIT3 myxoid
liposarcoma fusion protein, but not its wild-type counterparts
EWSR1 and DDIT3, selectively repressed the transcriptional
activity of cell lineage-specific marker genes in multipotent
mesenchymal C3H10T1/2 cells. Specifically, the osteoblastic
marker Opn promoter and chondrocytic marker Col11a2
promoter were repressed, while the adipocytic marker Ppar-c2
promoter was not affected (Figure 2). Cell phenotype is
determined by gene expression patterns, and the ability of a cell
to change its phenotype outside its lineage is achieved by the
activity of transcriptional regulators capable of reprogramming
gene networks [67]. Therefore, the above observation, selective
transcriptional repression by EWSR1-DDIT3, could partly reflect
the ability of EWSR1-DDIT3 to directly reprogram lineages of
multipotent mesenchymal cells (Figure 10A).
Previous studies have established the oncogenic potential of
TLS-DDIT3, another MLS-associated fusion protein [17,68]. Our
detailed inspection of supporting information tables from a recent
microarray-based analysis of TLS-DDIT3-transformed adipose-
derived mesenchymal stem cells revealed downregulation of Opn
and Col11a2 mRNA levels and preservation of Ppar-c gene
expression [18]. TLS belongs to the TET family of RNA-binding
proteins that consists of TLS, EWSR1, and TAF15 [69]. It is
possible to assume that EWSR1-DDIT3 functions in a manner
similar to TLS-DDIT3, because the two have the conserved
SYQG-rich amino terminal domain from EWSR1 or TLS, in
addition to share the same DNA-binding domain from DDIT3. If
so, our observations are consistent with these data.
This study also elucidated the possible molecular mechanisms
underlying the above discussed selective transcriptional repression.
First, the EWSR1-DDIT3 fusion protein (Figure 10B) might bind
to the functional C/EBP site within Opn and Col11a2 promoters
through interaction of its DNA-binding domain and interfere with
endogenous C/EBPb function (Figures 3, 4, 5 and 6). Of note,
previous observations showed that the analogous TLS-DDIT3
fusion protein prevented adipocytic differentiation by directly
interfering with C/EBPb function [70] and induced C/EBPb-
mediated interleukin 6 expression through heterodimerization
[71]. Second, EWSR1-DDIT3 (Figure 10C) might act in an
epigenetic manner to enhance histone deacetylation, DNA
Figure 6. EWSR1-DDIT3 affected recruitment of endogenous C/EBPb to the C/EBP site within Opn and Col11a2 promoters. Transient
ChIP assays using an antibody against C/EBPa, C/EBPb, or normal IgG. C3H10T1/2 cells were transfected with Opn (A) and Col11a2 (B) luciferase
reporter plasmids plus EWSR1-DDIT3 expression vectors. Promoter DNA fragments containing the C/EBP site (open box) were immunoprecipitated
with an antibody against C/EBPa or C/EBPb. Relative values reflecting protein–DNA interactions were calculated by adjusting corresponding signal
intensities to those of input levels. Experiments in duplicate were repeated at least three times, and the results are shown as averages below each
band. For C/EBPb, the relative value of immunoprecipitated Opn and Col11a2 promoter fragments significantly decreased after EWSR1-DDIT3
overexpression from 0.71 to 0.30 and 0.76 to 0.35, respectively. Asterisks (*) indicate statistical significance (p,0.05) calculated by unpaired t-test,
with p values of 0.022 for Opn and 0.0025 for Col11a2. As indicated by the arrows, the forward PCR primers are promoter sequence-specific primers
and locate upstream to the C/EBP site (open box), while the reverse PCR primer pGL3 is a plasmid-specific primer.
doi:10.1371/journal.pone.0036682.g006
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36682Figure 7. Involvement of histone deacetylases in transcriptional repression of Opn and Col11a2 promoters by EWSR1-DDIT3. (A and
B) Derepression of Opn (A) and Col11a2 (B) promoter activity by HDAC inhibitor, trichostatin A (TSA). C3H10T1/2 cells in duplicate plates were
cotransfected with promoter reporter plasmids plus EWSR1-DDIT3 expression vectors. Cells in one plate were assayed for luciferase activity 24 h after
treatment with TSA and compared with the cells from the other plate that were not treated with TSA. Luciferase activities from TSA-treated cells
relative to those from TSA-untreated cells are shown as fold derepression. Experiments in duplicate were repeated at least three times, and the results
are shown as averages 6 SE. Asterisks (*) indicate statistical significance (p,0.05) calculated by unpaired t-test, with p values of 0.0001 for Opn and
0.0277 for Col11a2. (C and D) Transient ChIP assays using an antibody against HDAC1 or normal IgG. C3H10T1/2 cells were transfected with Opn (C)
and Col11a2 (D) luciferase reporter plasmids plus EWSR1-DDIT3 expression vectors. Promoter DNA fragments containing the C/EBP site (open box)
were immunoprecipitated with an antibody against HDAC1. Relative values reflecting protein–DNA interactions were calculated by adjusting
corresponding signal intensities to those of input levels. Experiments in duplicate were repeated at least three times, and the results are shown as
averages below each band. Relative values of immunoprecipitated Opn and Col11a2 promoter fragments significantly increased after EWSR1-DDIT3
overexpression from 0.49 to 1.06 and 0.17 to 0.63, respectively. Asterisks (*) indicate statistical significance (p,0.05) calculated by unpaired t-test,
with p values of 0.0005 for Opn and 0.0021 for Col11a2. As indicated by the arrows, the forward PCR primers are promoter sequence-specific primers
and locate upstream to the C/EBP site (open box), while the reverse PCR primer pGL3 is a plasmid-specific primer.
doi:10.1371/journal.pone.0036682.g007
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tional repression site (Figures 7, 8 and 9). The epigenetic status has
been shown to influence the differentiation propensity of
transcription factor-based, directly reprogrammed inducible
multipotent stem cells [72]. Thus, we believe that EWSR1-
DDIT3-mediated transcriptional regulation may modulate the
target cell lineage through target gene-specific genetic and
epigenetic conversions.
The reason why Ppar-c2 promoter activity was not affected by
the EWSR1-DDIT3 fusion protein in mouse multipotent
mesenchymal C3H10T1/2 cells (Figure 2D) is not clear. However,
the observation that this activity seemed independent of C/EBP
sites in innate C3H10T1/2 cells (Figure 4C) suggests that
EWSR1-DDIT3 might selectively target C/EBP site-dependent
transcription. The related TLS-DDIT3 fusion protein has been
shown to repress Ppar-c2 promoter activity in U2OS human bone
sarcoma-derived cells [73] but not affect Ppar-c gene expression in
mouse bone marrow-derived mesenchymal progenitor cells [65].
These observations indicate that the molecular action of MLS-
associated fusion proteins may manifest in a cell type- and/or
species-dependent manner.
In conclusion, this study provides evidence that helps elucidate
the molecular mechanisms that underlie the contribution of the
EWSR1-DDIT3 fusion protein to the phenotypic selection of
targeted multipotent mesenchymal cells during MLS development.
These findings are fundamental to achieving a better understand-
ing of possible direct lineage reprogramming in oncogenic
sarcoma transformation mediated by fusion proteins.
Materials and Methods
Cell culture and RT-PCR
C3H10T1/2 cells (American Type Culture Collection (ATCC),
USA) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum (FBS), penicillin (100 U/
ml), and streptomycin (100 mg/ml) under 5% CO2 at 37uC. Total
RNA was extracted using the SV Total RNA Isolation System
(Promega, Madison, WI, USA), and 1.5 mg of total RNA was
converted to cDNA using the GeneAmpH Gold RNA PCR Core
Kit (Applied Biosystems, Foster City, CA, USA) in accordance
with the manufacturer’s instructions. The cDNA was advanced to
PCR amplification using PlatinumH Blue PCR SuperMix
(Invitrogen Life Technologies Corp., Carlsbad, CA, USA) and
primer sets specific for Opn, Col11a2, Ppar-c, and b-actin genes.
Primer sequences are summarized in Table 1. Each reaction
mixture contained 1 ml of cDNA, 20 ml of PlatinumH Blue PCR
SuperMix, and 10 pmol of each primer. Denaturation for 2 min at
95uC was followed by 30 cycles of 30 s at 95uC, 30 s at 60uC, and
30 s at 72uC, and a final extension of 7 min at 72uC. Aliquots of
the PCR products were electrophoresed on 2% agarose gels,
visualized by ethidium bromide staining, and directly sequenced
using the ABI PRISMH BigDyeH Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) to confirm correct amplifi-
cation in each reaction.
Plasmid constructs
The pGL3-Opn promoter construct was a gift from Dr. Piia
Aarnisalo, Helsinki, Finland [74]. The pGL3-Col11a2 promoter
construct has been described previously [54,75,76]. The pGL3-
Ppar-c2 promoter construct containing tandem repeats of C/EBP-
binding sites and its deletion mutants, pGL3-334 (lacking the distal
C/EBP-binding site) and pGL3-320 (lacking both C/EBP-binding
sites), were gifts from Dr. Xu Cao, Birmingham, AL, USA [36].
Variants of pGL3-Opn (pGL3-Opn mut) and pGL3-Col11a2
(pGL3-Col11a2 mut) were created by mutating potential C/EBP-
binding sites using the Gene Editor
TM Site-Directed Mutagenesis
kit (Promega), and successful mutagenesis was confirmed by DNA
sequencing. Primer sequences for mutagenesis will be forwarded
on request.
Figure 8. Significant derepression of the Col11a2 promoter,
but not the Opn promoter, by 5-Aza-29-deoxycytidine. (A and B)
Effect of the DNA methylation-resistant cytosine analog 5-Aza-29-
deoxycytidine (AZA) on Opn (A) and Col11a2 (B) promoter activities.
C3H10T1/2 cells in duplicate plates were cotransfected with promoter
reporter plasmids plus EWSR1-DDIT3 expression vectors. Cells in one
plate were assayed for luciferase activity 24 h after treatment with AZA
and compared with the cells from the other plate that were not treated
with AZA. Luciferase activities from AZA-treated cells relative to those
from AZA-untreated cells are shown as fold derepression. Experiments
in duplicate were repeated at least three times, and the results are
shown as averages 6 SE. An asterisk (*) indicates statistical significance
(p,0.05) calculated by unpaired t-test, with a p value of 0.0301 for
Col11a2. N.S., not significant.
doi:10.1371/journal.pone.0036682.g008
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was in-frame fused to exon 2 of DDIT3 with a serine (AGT) to
methionine (ATG) transition at the junction, was amplified by RT-
PCR from cDNA of MLS samples collected from the left thigh of a
19-year-old female [16] using the forward primer EWSR1 exon
1F 59-aatggcgtccacggattacagtacc-39 and reverse primer DDIT3
exon 4R 59-tcatgcttaatacagattcaccattcg-39. The products were
cloned into a pCRH2.1-TOPOH vector using the TOPO TA
CloningH Kit (Invitrogen Life Technologies Corp.), and the
correct sequences were confirmed by DNA sequencing. The
EcoRI fragment containing full-length EWSR1-DDIT3 cDNA
from correct clones was in-frame inserted into the EcoRI site of
the pFLAG-CMV4 mammalian expression vector (Sigma) to
produce pFLG-CMV4 EWSR1-DDIT3. Full-length EWSR1
cDNA was amplified from human placenta using the forward
primer EWSR1 exon 1F and reverse primer EWSR1 exon 17R
59-ctagtagggccgatct ctgcgctc-39. Full-length DDIT3 cDNA was
amplified from the abovementioned MLS sample using the
forward primer DDIT3 exon 2F 5 9-atgttcaagaaggaagtgtatcttc-39
and reverse primer DDIT3 exon 4R. The cDNAs were similarly
processed to produce pFLAG-CMV4 EWSR1 and pFLAG-
CMV4 DDIT3 expression vectors. The resultant proteins were
FLAG epitope tagged at the N termini. Two forms of mutant
EWSR1-DDIT3 expression vectors were generated by mutating
pFLG-CMV4 EWSR1-DDIT3 using the Gene Editor
TM Site-
Directed Mutagenesis kit (Promega), and successful mutagenesis
was confirmed by DNA sequencing. pFLAG-CMV4 EWSR1-
DDIT3 del LZ contained a stop codon just 59 to the codon for the
first leucine residue of the dimer forming LZ domain, so that the
entire LZ domain, composed of 38 C-terminal amino acid
residues, was deleted. Regarding pFLAG-CMV4 EWSR1-DDIT3
mut LZ, all five codons for leucine residues in the LZ domain were
changed to codons for glycine residues. Each correct FLAG-
tagged protein expression after transient transfection was con-
firmed by Western blotting using monoclonal anti-FLAGH M2
(Clone M2) antibody (F3165; Sigma) (Figure 11).
Figure 9. EWSR1-DDIT3 influenced the levels of acetylation or trimethylation at H3K9 around Opn and Col11a2 promoters. Transient
ChIP assays using an antibody against acetylated H3K9 or trimethylated H3K9. C3H10T1/2 cells were transfected with Opn (A) and Col11a2 (B)
luciferase reporter plasmids plus EWSR1-DDIT3 expression vectors. Promoter DNA fragments around C/EBP site were immunoprecipitated with an
antibody against acetylated H3K9 (H3K9-Ace) or trimethylated H3K9 (H3K9-Met) (top panels). Relative values reflecting protein–DNA interactions
were calculated by adjusting corresponding signal intensities to those of input levels. Experiments in duplicate were repeated at least three times,
and EWSR1-DDIT3-mediated changes in relative values are shown as averages 6 SE (bottom panels). (C) Ratio of H3K9-Ace versus H3K9-Met around
Opn and Col11a2 promoter constructs. Error bars indicate SE. Asterisks (*) indicate statistical significance (p,0.05) calculated by unpaired t-test. N.S.,
not significant.
doi:10.1371/journal.pone.0036682.g009
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PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36682Figure 10. Hypothetical diagram showing mechanisms by which EWSR1-DDIT3 exerts selective transcriptional repression in
multipotent mesenchymal cells. (A) Direct lineage reprogramming of multipotent mesenchymal cells (MMC) by EWSR1-DDIT3. (B) Genetic action
of EWSR1-DDIT3, which binds to the functional C/EBP site within target promoters through interaction of its DNA-binding domain and interferes with
endogenous C/EBPb function. (C) Epigenetic action introduced by EWSR1-DDIT3, enhancing histone deacetylation, DNA methylation, and histone 3
(H3) lysine 9 (K9) trimethylation at the transcriptional repression site. Tf, transcription factor; Ace, acetylation; CpG, cytosine–guanine dinucleotide;
HAT, histone acetyltransferase; HDAC, histone deacetylases; HMT, histone methyltransferases; DNMT, DNA methyltransferases; Met, methylation; TMZ,
temozolomide.
doi:10.1371/journal.pone.0036682.g010
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Transient transfection experiments were performed in
C3H10T1/2 cells seeded on 6-well plates using X-tremeGENE
9 reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA)
with 875 ng pGL3 reporter plasmid, 125 ng pFLAG-CMV4
expression vector, and 30 ng pRL-TK Renilla internal control
plasmid (Promega), according to the manufacturer’s instructions.
For luciferase assays, the cells were harvested 48 h after
transfection and luciferase activity was monitored using the Dual
LuciferaseH Reporter Assay System (Promega) on a TD-20/20
Luminometer (Turner Designs, Sunnyvale, CA, USA). Transfec-
tion in duplicate was repeated at least three times, and the
luciferase activity was normalized to internal controls. The results
are shown as average 6 standard errors. For inhibition of HDACs
or DNA methytransferases, transfected cells were treated with
100 ng/ml TSA (Sigma) or 5 mM AZA (Sigma), respectively, 24 h
before the luciferase assay and compared with transfected cells
without TSA or AZA treatment.
Western blotting
Cells transfected with each pFLAG-CMV4 expression vector in
a 10-cm dish were lysed with 1 ml of buffer A (10 mM Tris,
pH 7.5, 100 mM NaCl, 2.5 mM MgCl2, 0.5% Triton X-100, and
10 mM dithiothreitol (DTT)) supplemented with protease inhib-
itor cocktail and phosphatase inhibitor cocktail (Sigma). Twenty
microliters of 26SDS sample buffer and 4 ml of DTT were added
to 20 ml of the cell lysate. The sample mixtures were denatured for
5 min at 95uC, separated by SDS-PAGE using a 5–15% gradient
gel (Bio-Rad Laboratories, Hercules, CA, USA), transblotted onto
a polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laborato-
ries), and subjected to Western blotting using monoclonal anti-
FLAGH M2 (Clone M2) antibody (F3165; Sigma). Protein bands
were visualized on an X-ray film using the ECL Western blotting
detection system (GE Healthcare, Buckinghamshire, UK)
(Figure 11).
Transient ChIP assay
This is a well-accepted technique developed to study in vivo
binding of transcription factors to specific sites on promoters of
reporter constructs [37–39,77,78]. The ChIP-IT
TM Express
Enzymatic kit (Active Motif, Carlsbad, CA, USA) was used
according to the manufacturer’s instructions with minor modifi-
cations. In brief, C3H10T1/2 cells plated on three 10-cm dishes
were transiently transfected with 5 mg pGL3 reporter plasmid
together with 5 mg pFLAG-CMV4 expression vector per dish. The
cells were maintained for 48 h and cross-linked with 1%
formaldehyde for 5 min at room temperature. Soluble nuclear
material containing reporter plasmids was collected, enzymatically
sheared for 10 min at 37uC, and then immunoprecipitated with
3 mg antibody against N-terminal FLAG epitope tags (F3165;
Sigma), C/EBPa (14AA, sc-61X; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA), C/EBPb (C-19, sc-150X; Santa Cruz
Biotechnology Inc.), HDAC1 (C-19, sc-6298X; Santa Cruz
Biotechnology Inc.), acetyl-Histone H3 (Lys9) (07-352; Millipore,
Billerica, MA, USA), trimethyl-Histone H3 (Lys9) (07-442;
Millipore), or normal IgG (Santa Cruz Biotechnology Inc.). After
cross-linking was reversed, associated plasmid DNA was collected,
cleaned, and subjected to semiquantitative PCR using primer pairs
flanking C/EBP-binding sites within Opn and Col11a2 promoters.
The PCR products were electrophoresed on agarose gels and
visualized by ethidium bromide staining. Signal intensities were
measured using ImageJ software (NIH, Bethesda, MD, USA).
Relative values reflecting protein–DNA interactions were calcu-
lated by adjusting corresponding signal intensities to those of input
levels. PCR primers specific for pGL3-Opn and pGL3-Col11a2
reporters were developed and used to detect associated reporter
plasmids in each immunoprecipitation. Primer sequences included
the following: Opn F3 (forward; located at 2134 to 2112 from the
transcriptional start site), 59-ccacaaaaccagaggaggaagtg-39; Co-
Table 1. Primer Sets Used for RT-PCR.
Gene Direction Sequence GenBank Accession No.
Osteopontin Forward 59-ttacagcctgcacccagatcc-39 NM_009263.2
Reverse 59-cgtccatgtggtcatggctttc-39
Col11a2 Forward 59-aggagccccagaagcagt-39 NM_009926.1
Reverse 59-tggcaagggactggactc-39
Ppar-c2 Forward 59-aggccgagaaggagaagctgttg-39 NM_011146.3
Reverse 59-tggccacctctttgctctgctc-3
b-actin Forward 59-catccgtaaagacctctatgccaac-39 NM_007393.3
Reverse 59-atggagccaccgatccaca-39
doi:10.1371/journal.pone.0036682.t001
Figure 11. Protein expression by each FLAG-tagged expression
vector. Western blotting using an antibody against the N-terminal
FLAG epitope tag. Each protein band is indicated by an asterisk (*).
doi:10.1371/journal.pone.0036682.g011
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transcriptional start site), 5 9-ttctgcttcacctagtccag-3 9; and GL
primer 2 (reverse; located within the pGL3 plasmid backbone), 59-
ctttatgttttggcgtcttcca-39.
Immunoprecipitation and Western blotting
C3H10T1/2 cells transfected with the empty CMV promoter-
FLAG control plasmid or FLAG-tagged EWSR1-DDIT3 expres-
sion plasmid in a 10-cm dish were lysed with 1 ml of IP Lysis
Buffer (PIRCE, Rockford, IL, USA) supplemented with protease
inhibitor cocktail and phosphatase inhibitor cocktail (Sigma).
Immunoprecipitation of C/EBPa and C/EBPb was performed
using Dynabeads Protein A (Invitrogen Life Technologies Corp.)
according to manufacturer’s protocol. In brief, to 50 mlo f
Dynabeads Protein A, 20 ml of rabbit polyclonal anti-C/EBPa
antibody (14AA, sc-61; Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) or anti-C/EBPb antibody (C-19, sc-150; Santa
Cruz Biotechnology Inc.) were added and incubated for 1 h, and
500 mg protein of cell lysate added to the Dynabeads Protein A
conjugated antibody for overnight on a rotating device at 4uC.
Immunoprecipitated proteins were denatured for 5 min at 95uC,
separated by SDS-PAGE using a 5–15% gradient gel (Bio-Rad
Laboratories, Hercules, CA, USA), transblotted onto a polyviny-
lidene fluoride (PVDF) membrane (Bio-Rad), and subjected to
Western blotting using anti-C/EBPa antibody or anti-C/EBPb
antibody (Santa Cruz). Protein bands were visualized on X-ray
film using the ECL Plus Western blotting detection system (GE
Healthcare, Buckinghamshire, UK).
Real-time quantitative PCR assay
After transfection of the empty CMV promoter-FLAG control
plasmid or FLAG-tagged EWSR1-DDIT3 expression vector into
C3H10T1/2 cells, total RNA was extracted using the SV Total
RNA Isolation System (Promega, Madison, WI, USA), and 1 mgo f
total RNA was converted to cDNA using the GeneAmpH Gold
RNA PCR Core Kit (Applied Biosystems, Foster City, CA, USA)
with random hexamers as a primer in accordance with the
manufacturer’s instructions. For quantitative analysis of the
expression levels of C/EBPa mRNA and C/EBPb mRNA, real-
time quantitative PCR (qPCR) was performed on a Real-Time
PCR system (Mx3000P, Stratagene Japan K.K., Tokyo, Japan)
using SYBER Premix Ex Taq
TM (TaKaRa Bio, Inc. Shiga,
Japan). Real-time qPCR was performed using the specific primers
and levels of b-actin transcripts were used to normalize C/EBPa
and C/EBPb expression levels. Primer sequences were as follows:
C/EBPa 59-tgaacaagaacagcaacgag-39 and 59-tcactggtcacctccag-
cac-39; C/EBPb,5 9-gcgcgagcgcaacaacatcg-39 and 59-tgcttgaa-
caagttccgcag-39; b-actin, 59-tgttaccaactgggacgaca-39 and 59-
ggggtgttgaaggtctcaaa-39.
Statistics
Each sample was analyzed in duplicate, and experiments were
repeated at least three times. In all figures, data were shown as
average 6 standard errors (SE). All statistical analyses were
performed using Microsoft Office Excel (Microsoft Corp., Red-
mond, WA, USA). ANOVA followed by Tukey–Kramer post-hoc
test or unpaired t-test was used to determine statistical significance
(p values less than 0.05 were considered significant), where
applicable.
Supporting Information
Figure S1 Identification of potential C/EBP-binding
sites within Opn, Col11a2, and Ppar-c2 promoters in
hMSCs. The pGL3-Opn mut (A) and pGL3-Col11a2 mut (B)
showed significantly reduced promoter activity compared with
wild-type promoter constructs. (C) The pGL3-Ppar-c2 promoter
construct containing tandem repeat of C/EBP-binding sites and its
deletion mutant, pGL3-334 (lacking the distal C/EBP binding site
(I) in Figure 4C) exhibited comparable activity. The pGL3-320
(lacking the both C/EBP-binding sites) showed significantly
reduced promoter activity. The luciferase activities were expressed
as fold inductions; each activity relative to that of the promoter-less
reporter vector (pGL3 basic). Transfection in duplicate was
repeated at least three times, and the results are shown as
averages 6 SE. Asterisks (*) indicate statistical significance
(p,0.05) calculated by unpaired t-test on Opn (p=0.0044) or
Col11a2 (p=0.0075) promoter activity and ANOVA on Ppar-c2
promoter activity following Tukey–Kramer post-hoc test (N.S., not
significant, *p,0.05).
(TIF)
Figure S2 MV4 control or EWSR1-DDIT3. (A) The lysate
from C3H10T1/2 cells transfected with pFLAG-CMV4 control or
EWSR1-DDIT3 was immunoprecipitated (IP) with an anti-C/
EBPa antibody or an anti-C/EBPb antibody. IP samples were
electrophoresed and blotted with an anti-C/EBPa antibody or an
anti-C/EBPb antibody. Each protein band is indicated by an
asterisk (*). (B) Real-time quantitative PCR assay for the
endogenous mRNA levels of C/EBPa and C/EBPb in
C3H10T1/2 cells transfected with pFLAG-CMV4 control or
EWSR1-DDIT3. Each mRNA expression level was normalized to
that of b-actin. Similar results were obtained in three independent
experiments.
(TIF)
Figure S3 Repression of Opn or Col11a2 promoter
activity by anacardic acid (AA), a small molecule
compound which inhibits histone acetyltransferase
(HAT) activity of p300 and PCAF, was significantly
attenuated by overexpressing EWSR1-DDIT3. Effect of
AA on Opn (A) and Col11a2 (B) promoter activities. C3H10T1/2
cells in duplicate plates were cotransfected with each promoter
reporter construct plus EWSR1-DDIT3 expression vector. Cells in
one plate were assayed for luciferase activity 24 h after treatment
with AA (30 mM) and compared with the cells from the other plate
that were not treated with AA. Luciferase activities from AA-
treated cells relative to those from AA-untreated cells are shown as
fold repression. Experiments in duplicate were repeated at least
three times, and the results are shown as averages 6 SE. An
asterisk (*) indicates statistical significance (p,0.05) calculated by
unpaired t-test, with p values of 0.0336 for Opn and 0.0401 for
Col11a2.
(TIF)
Figure S4 Temozolomide (TMZ), a DNA methylating
chemotherapeutic drug, did not significantly influenced
on the Opn and Col11a2 promoter activities. Effect of
TMZ on Opn (A) and Col11a2 (B) promoter activities.
C3H10T1/2 cells in duplicate plates were cotransfected with
each promoter reporter constructs plus EWSR1-DDIT3 expres-
sion vector. Cells in one plate were assayed for luciferase activity
44 h after treatment with TMZ (50 mM) and compared with the
cells from the other plate that were not treated with TMZ.
Luciferase activities from TMZ-treated cells relative to those from
TMZ-untreated cells are shown as fold repression. Experiments in
duplicate were repeated at least three times, and the results are
shown as averages 6 SE. N.S., not significant.
(TIF)
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